Dambkowski Carl's most recent trade in Apogee Therapeutics Inc. was a trade of 8,000 Common Stock done . Disclosure was reported to the exchange on July 14, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Jul 2026 | 8,000 | 169,873 | - | 0 | Common Stock | |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 132.74 per share. | 01 Jul 2026 | 5,500 | 177,873 | - | 132.7 | 730,070 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2026 | 4,125 | 114,790 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.86 per share. | 01 Jul 2026 | 4,125 | 183,373 | - | 22.9 | 94,298 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 132.60 per share. | 22 Jun 2026 | 26,400 | 179,248 | - | 132.6 | 3,500,640 | Common Stock |
| Oruka Therapeutics Inc | Carl Dambkowski | Director | Sale of securities on an exchange or to another person at price $ 70.13 per share. | 11 Jun 2026 | 22,417 | 51,326 | - | 70.1 | 1,572,201 | Common Stock |
| Oruka Therapeutics Inc | Carl Dambkowski | Director | Sale of securities on an exchange or to another person at price $ 70.11 per share. | 11 Jun 2026 | 12,583 | 38,743 | - | 70.1 | 882,182 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 78.71 per share. | 03 Jun 2026 | 5,500 | 205,648 | - | 78.7 | 432,905 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.86 per share. | 03 Jun 2026 | 4,125 | 211,148 | - | 22.9 | 94,298 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2026 | 4,125 | 118,915 | - | - | Stock Option (Right to Buy) | |
| Oruka Therapeutics Inc | Carl Dambkowski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2026 | 9,136 | 9,136 | - | - | Stock Option (right to buy) | |
| Oruka Therapeutics Inc | Carl Dambkowski | Director | Sale of securities on an exchange or to another person at price $ 59.10 per share. | 21 May 2026 | 53,447 | 86,978 | - | 59.1 | 3,158,910 | Common Stock |
| Oruka Therapeutics Inc | Carl Dambkowski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.84 per share. | 21 May 2026 | 38,689 | 155,172 | - | 6.8 | 264,633 | Common Stock |
| Oruka Therapeutics Inc | Carl Dambkowski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2026 | 38,689 | 32,737 | - | - | Stock Option (right to buy) | |
| Oruka Therapeutics Inc | Carl Dambkowski | Director | Sale of securities on an exchange or to another person at price $ 58.43 per share. | 21 May 2026 | 38,318 | 140,425 | - | 58.4 | 2,238,794 | Common Stock |
| Oruka Therapeutics Inc | Carl Dambkowski | Director | Sale of securities on an exchange or to another person at price $ 59.97 per share. | 21 May 2026 | 13,235 | 73,743 | - | 60.0 | 793,662 | Common Stock |
| Oruka Therapeutics Inc | Carl Dambkowski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2026 | 11,904 | 10,952 | - | - | Warrant (right to buy) | |
| Oruka Therapeutics Inc | Carl Dambkowski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 21 May 2026 | 11,904 | 167,076 | - | 7.8 | 92,851 | Common Stock |
| Oruka Therapeutics Inc | Carl Dambkowski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2026 | 11,667 | 5,833 | - | - | Stock Option (right to buy) | |
| Oruka Therapeutics Inc | Carl Dambkowski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.77 per share. | 21 May 2026 | 11,667 | 178,743 | - | 11.8 | 137,321 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2026 | 4,125 | 123,040 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.86 per share. | 06 May 2026 | 4,125 | 212,523 | - | 22.9 | 94,298 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 83.92 per share. | 06 May 2026 | 3,700 | 208,823 | - | 83.9 | 310,504 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 84.60 per share. | 06 May 2026 | 1,800 | 207,023 | - | 84.6 | 152,280 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.86 per share. | 01 Apr 2026 | 4,125 | 213,898 | - | 22.9 | 94,298 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 4,125 | 127,165 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 85.33 per share. | 01 Apr 2026 | 2,702 | 208,498 | - | 85.3 | 230,562 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 84.31 per share. | 01 Apr 2026 | 2,698 | 211,200 | - | 84.3 | 227,468 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 85.89 per share. | 01 Apr 2026 | 100 | 208,398 | - | 85.9 | 8,589 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.86 per share. | 04 Mar 2026 | 4,125 | 215,273 | - | 22.9 | 94,298 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2026 | 4,125 | 131,290 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.33 per share. | 04 Mar 2026 | 3,225 | 212,048 | - | 70.3 | 226,814 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 71.98 per share. | 04 Mar 2026 | 2,075 | 209,973 | - | 72.0 | 149,359 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 73.26 per share. | 04 Mar 2026 | 200 | 209,773 | - | 73.3 | 14,652 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.86 per share. | 04 Feb 2026 | 4,125 | 216,648 | - | 22.9 | 94,298 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2026 | 4,125 | 135,415 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 64.88 per share. | 04 Feb 2026 | 2,481 | 214,167 | - | 64.9 | 160,967 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 65.83 per share. | 04 Feb 2026 | 1,420 | 212,747 | - | 65.8 | 93,479 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 66.85 per share. | 04 Feb 2026 | 1,299 | 211,448 | - | 66.8 | 86,838 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 68.94 per share. | 04 Feb 2026 | 200 | 211,148 | - | 68.9 | 13,788 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 67.88 per share. | 04 Feb 2026 | 100 | 211,348 | - | 67.9 | 6,788 | Common Stock |
| Oruka Therapeutics Inc | Carl Dambkowski | Director | Other type of transaction at price $ 0.00 per share. | 23 Jan 2026 | 116,483 | 116,483 | - | 0 | Common Stock | |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 77.90 per share. | 07 Jan 2026 | 14,820 | 213,449 | - | 77.9 | 1,154,478 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 14,025 | 139,540 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.86 per share. | 07 Jan 2026 | 14,025 | 231,223 | - | 22.9 | 320,612 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 77.13 per share. | 07 Jan 2026 | 2,954 | 228,269 | - | 77.1 | 227,842 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 79.04 per share. | 07 Jan 2026 | 826 | 212,623 | - | 79.0 | 65,287 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 80.06 per share. | 07 Jan 2026 | 100 | 212,523 | - | 80.1 | 8,006 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 83,690 | 83,690 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 75.00 per share. | 04 Dec 2025 | 10,900 | 271,108 | - | 75 | 817,500 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2025 | 8,060 | 153,565 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.86 per share. | 05 Nov 2025 | 8,060 | 292,793 | - | 22.9 | 184,252 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 55.58 per share. | 05 Nov 2025 | 5,607 | 282,686 | - | 55.6 | 311,637 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 53.62 per share. | 05 Nov 2025 | 2,300 | 290,493 | - | 53.6 | 123,326 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 54.83 per share. | 05 Nov 2025 | 2,200 | 288,293 | - | 54.8 | 120,626 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 56.51 per share. | 05 Nov 2025 | 678 | 282,008 | - | 56.5 | 38,314 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 39.80 per share. | 01 Oct 2025 | 5,110 | 284,733 | - | 39.8 | 203,378 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2025 | 2,385 | 161,625 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.86 per share. | 01 Oct 2025 | 2,385 | 289,843 | - | 22.9 | 54,521 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.82 per share. | 03 Sep 2025 | 2,535 | 233,738 | - | 37.8 | 95,874 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.55 per share. | 03 Sep 2025 | 190 | 233,548 | - | 38.6 | 7,325 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.78 per share. | 06 Aug 2025 | 2,725 | 236,273 | - | 37.8 | 102,951 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2025 | 7,365 | 164,010 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.86 per share. | 02 Jul 2025 | 7,365 | 249,088 | - | 22.9 | 168,364 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 44.77 per share. | 02 Jul 2025 | 6,409 | 242,679 | - | 44.8 | 286,931 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 45.49 per share. | 02 Jul 2025 | 2,935 | 239,744 | - | 45.5 | 133,513 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 46.26 per share. | 02 Jul 2025 | 746 | 238,998 | - | 46.3 | 34,510 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 36.96 per share. | 04 Jun 2025 | 2,725 | 241,723 | - | 37.0 | 100,716 | Common Stock |
| Oruka Therapeutics Inc | Carl Dambkowski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2025 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.75 per share. | 07 May 2025 | 2,725 | 244,448 | - | 35.8 | 97,419 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.56 per share. | 02 Apr 2025 | 2,471 | 248,562 | - | 35.6 | 87,869 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.59 per share. | 02 Apr 2025 | 889 | 247,173 | - | 37.6 | 33,418 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.03 per share. | 02 Apr 2025 | 500 | 248,062 | - | 37.0 | 18,515 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.48 per share. | 05 Mar 2025 | 1,590 | 251,033 | - | 30.5 | 48,463 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 40.69 per share. | 05 Feb 2025 | 3,520 | 252,623 | - | 40.7 | 143,229 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.86 per share. | 05 Feb 2025 | 795 | 256,143 | - | 22.9 | 18,174 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2025 | 795 | 171,375 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 47.21 per share. | 02 Jan 2025 | 2,486 | 255,448 | - | 47.2 | 117,364 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 46.42 per share. | 02 Jan 2025 | 1,499 | 257,934 | - | 46.4 | 69,584 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.86 per share. | 02 Jan 2025 | 1,360 | 259,433 | - | 22.9 | 31,090 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 1,360 | 172,170 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 47.92 per share. | 02 Jan 2025 | 100 | 255,348 | - | 47.9 | 4,792 | Common Stock |
| Apogee Therapeutics Inc | Dambkowski Carl | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 48.62 per share. | 11 Dec 2024 | 4,085 | 258,528 | - | 48.6 | 198,613 | Common Stock |
| Apogee Therapeutics Inc | Dambkowski Carl | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2024 | 1,815 | 173,530 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Dambkowski Carl | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.86 per share. | 11 Dec 2024 | 1,815 | 262,613 | - | 22.9 | 41,491 | Common Stock |
| Apogee Therapeutics Inc | Dambkowski Carl | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 11 Dec 2024 | 455 | 258,073 | - | 50 | 22,750 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2024 | 124,962 | 124,962 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 46.07 per share. | 04 Dec 2024 | 6,665 | 260,798 | - | 46.1 | 307,057 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 58.91 per share. | 06 Nov 2024 | 5,326 | 268,802 | - | 58.9 | 313,755 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 59.96 per share. | 06 Nov 2024 | 1,339 | 267,463 | - | 60.0 | 80,286 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 56.16 per share. | 02 Oct 2024 | 5,740 | 275,053 | - | 56.2 | 322,358 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 56.86 per share. | 02 Oct 2024 | 925 | 274,128 | - | 56.9 | 52,596 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 47.49 per share. | 04 Sep 2024 | 5,878 | 281,580 | - | 47.5 | 279,146 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 48.06 per share. | 04 Sep 2024 | 787 | 280,793 | - | 48.1 | 37,823 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 40.47 per share. | 07 Aug 2024 | 6,523 | 288,270 | - | 40.5 | 263,986 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 42.56 per share. | 07 Aug 2024 | 670 | 287,458 | - | 42.6 | 28,515 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 41.09 per share. | 07 Aug 2024 | 142 | 288,128 | - | 41.1 | 5,835 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.29 per share. | 03 Jul 2024 | 3,852 | 296,936 | - | 37.3 | 143,641 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.16 per share. | 03 Jul 2024 | 2,143 | 294,793 | - | 38.2 | 81,777 | Common Stock |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 175,345 | 175,345 | - | - | Stock Option (Right to Buy) |